SCHEMBL5870512

SCHEMBL5870512

CC(C)(C)CC(SCc1csc2ccccc12)C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 2/20 0.44
TAAR1 Q96RJ0 1/20 0.41
CTSL P07711 1/20 0.41
CTSS P25774 1/20 0.41
CTSK P43235 1/20 0.41
SMN1; SMN2 Q16637 4/20 0.40
TP53 P04637 2/20 0.40
RXFP1 Q9HBX9 1/20 0.40
POLB P06746 1/20 0.39
IDO1 P14902 1/20 0.38
CMA1 P23946 1/20 0.37
HDAC6 Q9UBN7 2/20 0.37
FAAH O00519 1/20 0.37
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HDAC1 Q13547 1/20 0.36
MTNR1A P48039 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5870553 0.75 CYP2A6 (0.44) CYP2A6TAAR1CTSLCTSSCTSK
SCHEMBL5870185 0.74 CYP2A6 (0.43) CYP2A6TAAR1CTSLCTSSCTSK
SCHEMBL5870635 0.72 CYP2C19 (0.47) CTSSCTSKSMN1; SMN2POLBALDH1A1
SCHEMBL5870380 0.70 SLC1A3 (0.40) CTSSCTSKSMN1; SMN2POLBALDH1A1
SCHEMBL7313868 0.70 CYP2A6 (0.59) CYP2A6TAAR1CTSLCTSSCTSK
SCHEMBL8432969 0.70 CYP2A6 (0.54) CYP2A6TAAR1CTSLCTSSCTSK
SCHEMBL14947066 0.70 CYP2A6 (0.54) CYP2A6TAAR1CTSLCTSSCTSK
SCHEMBL21309831 0.70 CYP2A6 (0.54) CYP2A6TAAR1CTSLCTSSCTSK
SCHEMBL10950583 0.70 CYP2A6 (0.54) CYP2A6TAAR1CTSLCTSSCTSK
SCHEMBL8481116 0.69 CYP2A6 (0.58) CYP2A6TAAR1CTSLCTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7132449-B2 Inhibitors of cruzipain and other cysteine proteases AMURA THERAPEUTICS LIMITED (GB) 2006-11-07 US disclosed
US-20040127424-A1 Inhibitors of cruzipain and other cysteine proteases AMURA THERAPUTICS LIMITED (GB) 2004-07-01 US disclosed
EP-1358174-A2 INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES Amura Therapeutics Limited (GB) 2003-11-05 EP disclosed
WO-2002057248-A2 INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES AMURA THERAPEUTICS LIMITED (GB) 2002-07-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040127424-A1 Inhibitors of cruzipain and other cysteine proteases CPN1, CTRL, CPA1 CYP2A6 4080/4885TAAR1 3330/4885CTSL 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.